<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="11" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font6" size="10" family="Giovanni-BookItalic,Italic" color="#000000"/>
	<fontspec id="font7" size="10" family="Symbol" color="#000000"/>
	<fontspec id="font8" size="8" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font9" size="8" family="GillSans" color="#000000"/>
	<fontspec id="font10" size="8" family="GillSans,BoldItalic" color="#000000"/>
<text top="41" left="55" width="110" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">Nuclear Receptor 2005, 3 :4<i>Nuclear Receptor</i></text>
<text top="41" left="370" width="184" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="1" tag_type="text">http://www.nuclear-receptor.com/content/3/1/4</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t3" reading_order_no="123" segment_no="13" tag_type="text">Page 4 of 7<b>3</b></text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t4" reading_order_no="124" segment_no="14" tag_type="text">(page number not for citation purposes)</text>
<text top="286" left="55" width="241" height="9" font="font4" id="p1_t5" reading_order_no="33" segment_no="7" tag_type="text">associated with the C2528 was not linked to raised choles-</text>
<text top="298" left="55" width="241" height="9" font="font4" id="p1_t6" reading_order_no="34" segment_no="7" tag_type="text">terol levels. When a combined endpoint of death from all</text>
<text top="310" left="55" width="241" height="9" font="font4" id="p1_t7" reading_order_no="35" segment_no="7" tag_type="text">cause, and non-fatal myocardial infarction was consid-<i>(page number not for citation purposes)</i></text>
<text top="322" left="55" width="241" height="9" font="font4" id="p1_t8" reading_order_no="36" segment_no="7" tag_type="text">ered in the same model it was found that the V162 contin-</text>
<text top="333" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="37" segment_no="7" tag_type="text">ued to demonstrate a reduced risk of an event although</text>
<text top="345" left="55" width="241" height="9" font="font4" id="p1_t10" reading_order_no="38" segment_no="7" tag_type="text">the association was attenuated (HR 0.52, 95%CI 0.28–</text>
<text top="357" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="39" segment_no="7" tag_type="text">0.98, p = 0.044). C2528 again demonstrated an increased</text>
<text top="369" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="40" segment_no="7" tag_type="text">risk although this was now weak and borderline non-sig-</text>
<text top="380" left="55" width="208" height="9" font="font4" id="p1_t13" reading_order_no="41" segment_no="7" tag_type="text">nificant (HR 1.52, 95% CI 0.99–2.31, p = 0.052).</text>
<text top="404" left="55" width="53" height="10" font="font5" id="p1_t14" reading_order_no="42" segment_no="9" tag_type="title">Discussion</text>
<text top="416" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="43" segment_no="10" tag_type="text">It has been previously demonstrated that two common</text>
<text top="427" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="44" segment_no="10" tag_type="text">variants at the PPARA locus are associated with opposing</text>
<text top="439" left="55" width="241" height="9" font="font4" id="p1_t17" reading_order_no="45" segment_no="10" tag_type="text">risks of development of atherosclerotic vascular disease<b>Discussion</b></text>
<text top="451" left="55" width="241" height="9" font="font4" id="p1_t18" reading_order_no="46" segment_no="10" tag_type="text">and myocardial infarction in two separate populations of</text>
<text top="463" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="47" segment_no="10" tag_type="text">non-diabetic male subjects taking part in the LOCAT and</text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="48" segment_no="10" tag_type="text">NPHS2 studies [11]. Individuals with type 2 diabetes are<i>PPARA </i></text>
<text top="286" left="313" width="241" height="9" font="font4" id="p1_t21" reading_order_no="49" segment_no="8" tag_type="text">however particularly susceptible to atherosclerotic mac-</text>
<text top="296" left="313" width="241" height="13" font="font4" id="p1_t22" reading_order_no="50" segment_no="8" tag_type="text">rovascular disease, and PPAR α activators such as the</text>
<text top="310" left="313" width="241" height="9" font="font4" id="p1_t23" reading_order_no="51" segment_no="8" tag_type="text">fibrate group of drugs appear to be particularly beneficial</text>
<text top="322" left="313" width="241" height="9" font="font4" id="p1_t24" reading_order_no="52" segment_no="8" tag_type="text">in reducing cardiovascular events in this group of patients</text>
<text top="333" left="313" width="241" height="9" font="font4" id="p1_t25" reading_order_no="53" segment_no="8" tag_type="text">[13]. In this study we have confirmed the observation that<a href="">[11]. Individu</a>als with type 2 diabetes are</text>
<text top="345" left="313" width="241" height="9" font="font4" id="p1_t26" reading_order_no="54" segment_no="8" tag_type="text">V162 is associated with a decreased risk and the C2528</text>
<text top="357" left="313" width="241" height="9" font="font4" id="p1_t27" reading_order_no="55" segment_no="8" tag_type="text">variant is associated with an increased risk of cardiovascu-</text>
<text top="369" left="313" width="241" height="9" font="font4" id="p1_t28" reading_order_no="56" segment_no="8" tag_type="text">lar disease and that this observation can be extended to</text>
<text top="380" left="313" width="241" height="9" font="font4" id="p1_t29" reading_order_no="57" segment_no="8" tag_type="text">individuals with type 2 diabetes. We also found that the</text>
<text top="392" left="313" width="241" height="9" font="font4" id="p1_t30" reading_order_no="58" segment_no="8" tag_type="text">association is similar in both male and female individu-</text>
<text top="404" left="313" width="241" height="9" font="font4" id="p1_t31" reading_order_no="59" segment_no="8" tag_type="text">als. Finally we confirm a recent finding that these variants</text>
<text top="416" left="313" width="241" height="9" font="font4" id="p1_t32" reading_order_no="60" segment_no="8" tag_type="text">are associated with opposing influences on age of diagno-<a href="">[13</a>]. In this study we have confirmed the observation that</text>
<text top="427" left="313" width="241" height="9" font="font4" id="p1_t33" reading_order_no="61" segment_no="8" tag_type="text">sis with type 2 diabetes [12], and that the C2528 variant is</text>
<text top="439" left="313" width="241" height="9" font="font4" id="p1_t34" reading_order_no="62" segment_no="8" tag_type="text">also associated with significantly higher total cholesterol</text>
<text top="451" left="313" width="158" height="9" font="font4" id="p1_t35" reading_order_no="63" segment_no="8" tag_type="text">and calculated LDL cholesterol levels.</text>
<text top="87" left="55" width="349" height="7" font="font8" id="p1_t36" reading_order_no="2" segment_no="2" tag_type="title">Table 5: Influence of genotype and inferred haplotypes on age diagnosed with type 2 diabetes.</text>
<text top="105" left="339" width="56" height="7" font="font8" id="p1_t37" reading_order_no="3" segment_no="3" tag_type="table">Age diagnosed</text>
<text top="127" left="184" width="15" height="7" font="font9" id="p1_t38" reading_order_no="4" segment_no="3" tag_type="table">Beta</text>
<text top="127" left="309" width="24" height="7" font="font9" id="p1_t39" reading_order_no="5" segment_no="3" tag_type="table">95% CI</text>
<text top="127" left="433" width="4" height="7" font="font9" id="p1_t40" reading_order_no="6" segment_no="3" tag_type="table">p<a href=""> [12</a>], and that the C2528 variant is</text>
<text top="149" left="59" width="23" height="7" font="font8" id="p1_t41" reading_order_no="7" segment_no="3" tag_type="table">V162*</text>
<text top="149" left="184" width="10" height="7" font="font9" id="p1_t42" reading_order_no="8" segment_no="3" tag_type="table">2.6</text>
<text top="149" left="309" width="24" height="7" font="font9" id="p1_t43" reading_order_no="9" segment_no="3" tag_type="table">0.2–5.1<b>Table 5: Influence of genotype and inferred haplotypes on age diagnosed with type 2 diabetes.</b></text>
<text top="149" left="433" width="18" height="7" font="font9" id="p1_t44" reading_order_no="10" segment_no="3" tag_type="table">0.034<b>Age diagnosed</b></text>
<text top="160" left="59" width="29" height="7" font="font8" id="p1_t45" reading_order_no="11" segment_no="3" tag_type="table">C2528†</text>
<text top="160" left="184" width="13" height="7" font="font9" id="p1_t46" reading_order_no="12" segment_no="3" tag_type="table">-1.1</text>
<text top="160" left="309" width="27" height="7" font="font9" id="p1_t47" reading_order_no="13" segment_no="3" tag_type="table">-2.0–0.2</text>
<text top="160" left="433" width="18" height="7" font="font9" id="p1_t48" reading_order_no="14" segment_no="3" tag_type="table">0.022<b>V162*</b></text>
<text top="180" left="59" width="40" height="7" font="font8" id="p1_t49" reading_order_no="15" segment_no="3" tag_type="table">Haplotype</text>
<text top="190" left="59" width="46" height="7" font="font8" id="p1_t50" reading_order_no="16" segment_no="3" tag_type="table">L162-G2582</text>
<text top="190" left="184" width="11" height="7" font="font9" id="p1_t51" reading_order_no="17" segment_no="3" tag_type="table">Ref</text>
<text top="201" left="59" width="46" height="7" font="font8" id="p1_t52" reading_order_no="18" segment_no="3" tag_type="table">L162-C2528<b>C2528†</b></text>
<text top="201" left="184" width="17" height="7" font="font9" id="p1_t53" reading_order_no="19" segment_no="3" tag_type="table">-0.40</text>
<text top="201" left="309" width="40" height="7" font="font9" id="p1_t54" reading_order_no="20" segment_no="3" tag_type="table">-1.25 – 0.45</text>
<text top="201" left="433" width="14" height="7" font="font9" id="p1_t55" reading_order_no="21" segment_no="3" tag_type="table">0.36</text>
<text top="211" left="59" width="47" height="7" font="font8" id="p1_t56" reading_order_no="22" segment_no="3" tag_type="table">V162-G2528<b>Haplotype</b></text>
<text top="211" left="184" width="14" height="7" font="font9" id="p1_t57" reading_order_no="23" segment_no="3" tag_type="table">3.89<b>L162-G2582</b></text>
<text top="211" left="309" width="37" height="7" font="font9" id="p1_t58" reading_order_no="24" segment_no="3" tag_type="table">1.26 – 6.51</text>
<text top="211" left="433" width="18" height="7" font="font9" id="p1_t59" reading_order_no="25" segment_no="3" tag_type="table">0.004<b>L162-C2528</b></text>
<text top="221" left="59" width="47" height="7" font="font8" id="p1_t60" reading_order_no="26" segment_no="3" tag_type="table">V162-C2528</text>
<text top="221" left="184" width="17" height="7" font="font9" id="p1_t61" reading_order_no="27" segment_no="3" tag_type="table">-0.28</text>
<text top="221" left="309" width="40" height="7" font="font9" id="p1_t62" reading_order_no="28" segment_no="3" tag_type="table">-1.65 – 1.10</text>
<text top="221" left="433" width="14" height="7" font="font9" id="p1_t63" reading_order_no="29" segment_no="3" tag_type="table">0.69<b>V162-G2528</b></text>
<text top="243" left="59" width="71" height="7" font="font9" id="p1_t64" reading_order_no="30" segment_no="4" tag_type="text">*Co-dominant model</text>
<text top="253" left="59" width="63" height="7" font="font9" id="p1_t65" reading_order_no="31" segment_no="5" tag_type="text">† Dominant model</text>
<text top="262" left="59" width="119" height="7" font="font9" id="p1_t66" reading_order_no="32" segment_no="6" tag_type="text">Both variants included in the model</text>
<text top="493" left="55" width="497" height="7" font="font8" id="p1_t67" reading_order_no="64" segment_no="11" tag_type="text">Table 6: Prospective model of PPARA variants and non-fatal myocardial infarction risk in the Go-DARTs cohort. A full set of data was<b>V162-C2528</b></text>
<text top="502" left="55" width="492" height="7" font="font8" id="p1_t68" reading_order_no="65" segment_no="11" tag_type="text">available on 1806 individuals, 108 recorded non fatal myocardial infarctions during the period of observation, with a total of 94497.6</text>
<text top="512" left="55" width="326" height="7" font="font8" id="p1_t69" reading_order_no="66" segment_no="11" tag_type="text">months of observation. Both PPARA variants were analysed using a co-dominant model.</text>
<text top="530" left="217" width="51" height="7" font="font8" id="p1_t70" reading_order_no="67" segment_no="12" tag_type="table">Hazard Ratio</text>
<text top="530" left="354" width="26" height="7" font="font8" id="p1_t71" reading_order_no="68" segment_no="12" tag_type="table">95% CI</text>
<text top="530" left="489" width="5" height="7" font="font8" id="p1_t72" reading_order_no="69" segment_no="12" tag_type="table">P</text>
<text top="552" left="108" width="20" height="7" font="font8" id="p1_t73" reading_order_no="70" segment_no="12" tag_type="table">V162</text>
<text top="552" left="235" width="14" height="7" font="font9" id="p1_t74" reading_order_no="71" segment_no="12" tag_type="table">0.31<b>Table 6: Prospective model of </b></text>
<text top="552" left="352" width="31" height="7" font="font9" id="p1_t75" reading_order_no="72" segment_no="12" tag_type="table">0.10 0.93<i><b>PPARA </b></i></text>
<text top="552" left="483" width="18" height="7" font="font9" id="p1_t76" reading_order_no="73" segment_no="12" tag_type="table">0.037<b>variants and non-fatal myocardial infarction risk in the Go-DARTs cohort. A full set of data was </b></text>
<text top="562" left="105" width="25" height="7" font="font8" id="p1_t77" reading_order_no="74" segment_no="12" tag_type="table">C2528<b>available on 1806 individuals, 108 recorded non fatal myocardial infarctions during the period of observation, with a total of 94497.6 </b></text>
<text top="562" left="235" width="14" height="7" font="font9" id="p1_t78" reading_order_no="75" segment_no="12" tag_type="table">2.77<b>months of observation. Both </b></text>
<text top="562" left="352" width="31" height="7" font="font9" id="p1_t79" reading_order_no="76" segment_no="12" tag_type="table">1.34 5.75<i><b>PPARA </b></i></text>
<text top="562" left="483" width="18" height="7" font="font9" id="p1_t80" reading_order_no="77" segment_no="12" tag_type="table">0.006<b>variants were analysed using a co-dominant model.</b></text>
<text top="573" left="101" width="34" height="7" font="font8" id="p1_t81" reading_order_no="78" segment_no="12" tag_type="table">Smoking<b>Hazard Ratio</b></text>
<text top="573" left="235" width="14" height="7" font="font9" id="p1_t82" reading_order_no="79" segment_no="12" tag_type="table">1.39<b>95% CI</b></text>
<text top="573" left="352" width="31" height="7" font="font9" id="p1_t83" reading_order_no="80" segment_no="12" tag_type="table">0.93 2.10<b>P</b></text>
<text top="573" left="483" width="18" height="7" font="font9" id="p1_t84" reading_order_no="81" segment_no="12" tag_type="table">0.112<b>V162</b></text>
<text top="583" left="103" width="29" height="7" font="font8" id="p1_t85" reading_order_no="82" segment_no="12" tag_type="table">Gender</text>
<text top="583" left="235" width="14" height="7" font="font9" id="p1_t86" reading_order_no="83" segment_no="12" tag_type="table">0.72</text>
<text top="583" left="352" width="31" height="7" font="font9" id="p1_t87" reading_order_no="84" segment_no="12" tag_type="table">0.48 1.08</text>
<text top="583" left="483" width="18" height="7" font="font9" id="p1_t88" reading_order_no="85" segment_no="12" tag_type="table">0.107<b>C2528</b></text>
<text top="593" left="80" width="75" height="7" font="font8" id="p1_t89" reading_order_no="86" segment_no="12" tag_type="table">Age at recruitment</text>
<text top="593" left="235" width="14" height="7" font="font9" id="p1_t90" reading_order_no="87" segment_no="12" tag_type="table">1.05</text>
<text top="593" left="352" width="31" height="7" font="font9" id="p1_t91" reading_order_no="88" segment_no="12" tag_type="table">1.02 1.07</text>
<text top="593" left="480" width="23" height="7" font="font9" id="p1_t92" reading_order_no="89" segment_no="12" tag_type="table">&lt;0.001<b>Smoking</b></text>
<text top="603" left="84" width="67" height="7" font="font8" id="p1_t93" reading_order_no="90" segment_no="12" tag_type="table">Insulin treatment</text>
<text top="603" left="235" width="14" height="7" font="font9" id="p1_t94" reading_order_no="91" segment_no="12" tag_type="table">2.56</text>
<text top="603" left="352" width="31" height="7" font="font9" id="p1_t95" reading_order_no="92" segment_no="12" tag_type="table">1.69 3.89</text>
<text top="603" left="480" width="23" height="7" font="font9" id="p1_t96" reading_order_no="93" segment_no="12" tag_type="table">&lt;0.001<b>Gender</b></text>
<text top="614" left="85" width="64" height="7" font="font8" id="p1_t97" reading_order_no="94" segment_no="12" tag_type="table">Prevalent angina</text>
<text top="614" left="235" width="14" height="7" font="font9" id="p1_t98" reading_order_no="95" segment_no="12" tag_type="table">5.64</text>
<text top="614" left="352" width="31" height="7" font="font9" id="p1_t99" reading_order_no="96" segment_no="12" tag_type="table">3.80 8.40</text>
<text top="614" left="480" width="23" height="7" font="font9" id="p1_t100" reading_order_no="97" segment_no="12" tag_type="table">&lt;0.001<b>Age at recruitment</b></text>
<text top="624" left="67" width="103" height="7" font="font8" id="p1_t101" reading_order_no="98" segment_no="12" tag_type="table">Prevalent cerebrovascular</text>
<text top="633" left="104" width="28" height="7" font="font8" id="p1_t102" reading_order_no="99" segment_no="12" tag_type="table">disease</text>
<text top="624" left="235" width="14" height="7" font="font9" id="p1_t103" reading_order_no="100" segment_no="12" tag_type="table">1.29</text>
<text top="624" left="352" width="31" height="7" font="font9" id="p1_t104" reading_order_no="101" segment_no="12" tag_type="table">0.67 2.51<b>Insulin treatment</b></text>
<text top="624" left="483" width="18" height="7" font="font9" id="p1_t105" reading_order_no="102" segment_no="12" tag_type="table">0.445</text>
<text top="643" left="76" width="85" height="7" font="font8" id="p1_t106" reading_order_no="103" segment_no="12" tag_type="table">Prevalent myocardial</text>
<text top="653" left="99" width="37" height="7" font="font8" id="p1_t107" reading_order_no="104" segment_no="12" tag_type="table">infarction</text>
<text top="643" left="235" width="14" height="7" font="font9" id="p1_t108" reading_order_no="105" segment_no="12" tag_type="table">3.90<b>Prevalent angina</b></text>
<text top="643" left="352" width="31" height="7" font="font9" id="p1_t109" reading_order_no="106" segment_no="12" tag_type="table">2.60 5.81</text>
<text top="643" left="480" width="23" height="7" font="font9" id="p1_t110" reading_order_no="107" segment_no="12" tag_type="table">&lt;0.001</text>
<text top="673" left="59" width="44" height="7" font="font8" id="p1_t111" reading_order_no="108" segment_no="12" tag_type="table">Haplotypes</text>
<text top="683" left="79" width="46" height="7" font="font8" id="p1_t112" reading_order_no="109" segment_no="12" tag_type="table">L162-G2582<b>Prevalent cerebrovascular </b></text>
<text top="683" left="237" width="11" height="7" font="font9" id="p1_t113" reading_order_no="110" segment_no="12" tag_type="table">Ref<b>disease</b></text>
<text top="694" left="79" width="46" height="7" font="font8" id="p1_t114" reading_order_no="111" segment_no="12" tag_type="table">L162-C2528</text>
<text top="694" left="235" width="14" height="7" font="font9" id="p1_t115" reading_order_no="112" segment_no="12" tag_type="table">1.68</text>
<text top="694" left="351" width="32" height="7" font="font9" id="p1_t116" reading_order_no="113" segment_no="12" tag_type="table">1.16–2.43</text>
<text top="694" left="483" width="18" height="7" font="font9" id="p1_t117" reading_order_no="114" segment_no="12" tag_type="table">0.006<b>Prevalent myocardial </b></text>
<text top="704" left="79" width="47" height="7" font="font8" id="p1_t118" reading_order_no="115" segment_no="12" tag_type="table">V162-G2528<b>infarction</b></text>
<text top="704" left="235" width="14" height="7" font="font9" id="p1_t119" reading_order_no="116" segment_no="12" tag_type="table">0.54</text>
<text top="704" left="351" width="32" height="7" font="font9" id="p1_t120" reading_order_no="117" segment_no="12" tag_type="table">0.20–1.48</text>
<text top="704" left="485" width="14" height="7" font="font9" id="p1_t121" reading_order_no="118" segment_no="12" tag_type="table">0.23</text>
<text top="714" left="79" width="47" height="7" font="font8" id="p1_t122" reading_order_no="119" segment_no="12" tag_type="table">V162-C2528<b>Haplotypes</b></text>
<text top="714" left="235" width="14" height="7" font="font9" id="p1_t123" reading_order_no="120" segment_no="12" tag_type="table">0.96<b>L162-G2582</b></text>
<text top="714" left="351" width="32" height="7" font="font9" id="p1_t124" reading_order_no="121" segment_no="12" tag_type="table">0.48–1.94</text>
<text top="714" left="485" width="14" height="7" font="font9" id="p1_t125" reading_order_no="122" segment_no="12" tag_type="table">0.91<b>L162-C2528</b></text>
</page>
</pdf2xml>
